1. Introduction {#sec1-jcm-08-00143}
===============

Capillary leak syndrome (CLS), also known as vascular leak syndrome (VLS), is a rare but fatal disease, and an idiopathic form of CLS was first reported by Clarkson in 1960 \[[@B1-jcm-08-00143]\]. Patients with CLS show a profound increase of capillary permeability, which can result in the leakage of plasma with proteins out from capillaries, resulting in clinical features such as edema, hypotension, hypoalbuminemia, or hemoconcentration \[[@B2-jcm-08-00143],[@B3-jcm-08-00143],[@B4-jcm-08-00143]\]. Most cases of CLS are classified as idiopathic forms, and its pathogenesis has not been elucidated yet. It may also develop as a secondary form, preceded by autoimmune diseases, infections, snakebites, and drugs \[[@B5-jcm-08-00143]\]. Cancer and chemotherapy are also considered to be important causes of secondary CLS, but the underlying mechanisms remain mostly elusive \[[@B4-jcm-08-00143],[@B6-jcm-08-00143]\]. CLS shows a high mortality rate, with one-year and five-year survival rates being 89% and 73%, respectively, in idiopathic forms \[[@B7-jcm-08-00143]\]. If prophylactic treatment including intravenous immunoglobulin (IVIG) is provided, disease-specific mortality seems to decrease in idiopathic CLS \[[@B3-jcm-08-00143],[@B7-jcm-08-00143],[@B8-jcm-08-00143]\]. However, there is no established treatment for secondary CLS, and supportive therapy with fluid management may be the most important element \[[@B5-jcm-08-00143]\]. Currently, exact treatment guidelines for CLS do not exist \[[@B8-jcm-08-00143],[@B9-jcm-08-00143],[@B10-jcm-08-00143],[@B11-jcm-08-00143]\]. Moreover, the capillary leak phenomenon can be similar between idiopathic CLS and secondary forms of CLS due to drugs, but the pathophysiology of them may be somewhat different.

CLS has also been reported as an adverse event in cancer patients receiving different types of anti-cancer treatments \[[@B3-jcm-08-00143]\]. However, there has been a lack of awareness of CLS by oncologists due to the non-specific symptoms of this disease \[[@B3-jcm-08-00143]\], and the incidence of CLS according to the different types of anti-cancer agents or therapy has not been systematically investigated.

Thus, in this study, we conducted a systematic review and meta-analysis to estimate the incidence proportion of CLS in cancer patients who received specific anti-cancer treatment or therapy, including bone marrow transplantation (BMT).

2. Methods {#sec2-jcm-08-00143}
==========

2.1. Literature Search Strategy and Study Selection {#sec2dot1-jcm-08-00143}
---------------------------------------------------

We followed the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist for this systematic review ([Supplementary Table S1](#app1-jcm-08-00143){ref-type="app"}). Two investigators (K.H.L. and I.R.L.) manually searched the literature (PubMed and EMBASE) to find original studies that reported cases of CLS as an adverse event in cancer patients who received specific cancer treatment or BMT. The search terms were: "(Capillary leak OR Vascular leak) AND (cancer OR carcinoma OR neoplasm OR tumor)", and the date of the last search was 15 July 2018. If there was a discrepancy for the inclusion/exclusion of the respective article, it was discussed and resolved by consensus among three investigators (J.I.S., K.H.L., and I.R.L.). The full literature search strategy is presented in [Figure 1](#jcm-08-00143-f001){ref-type="fig"}.

The eligibility criteria for inclusion were: studies on (1) CLS that was an adverse event of cancer treatment-related drugs; and (2) CLS that developed after BMT; and the exclusion criteria were: studies on (1) CLS that were caused by idiopathic forms, infection, or surgery; and (2) CLS attributed to cancer itself, or (3) missing raw data from the original study reporting on CLS as an adverse event of cancer treatment. Our initial search yielded 4612 articles, but we finally included 62 clinical trials (or studies) that met the inclusion criteria for this systematic review.

2.2. Data Extraction {#sec2dot2-jcm-08-00143}
--------------------

For each eligible clinical trial (or study), we recorded the first author, publication year, journal name, period of study, country, total number of patients, number of patients who developed CLS, diagnosed cancer type, causative drugs, and the dose of drugs.

2.3. Analyses of Clinical Trials (or Studies) {#sec2dot3-jcm-08-00143}
---------------------------------------------

The incidence of CLS for each study was estimated by calculating the ratio between the number of CLS patients and the total number of cancer patients who received the causative drug or BMT. The data for each study are presented in [Table 1](#jcm-08-00143-t001){ref-type="table"} \[[@B12-jcm-08-00143],[@B13-jcm-08-00143],[@B14-jcm-08-00143],[@B15-jcm-08-00143],[@B16-jcm-08-00143],[@B17-jcm-08-00143],[@B18-jcm-08-00143],[@B19-jcm-08-00143],[@B20-jcm-08-00143],[@B21-jcm-08-00143],[@B22-jcm-08-00143],[@B23-jcm-08-00143],[@B24-jcm-08-00143],[@B25-jcm-08-00143],[@B26-jcm-08-00143],[@B27-jcm-08-00143],[@B28-jcm-08-00143],[@B29-jcm-08-00143],[@B30-jcm-08-00143],[@B31-jcm-08-00143],[@B32-jcm-08-00143],[@B33-jcm-08-00143],[@B34-jcm-08-00143],[@B35-jcm-08-00143],[@B36-jcm-08-00143],[@B37-jcm-08-00143],[@B38-jcm-08-00143],[@B39-jcm-08-00143],[@B40-jcm-08-00143],[@B41-jcm-08-00143],[@B42-jcm-08-00143],[@B43-jcm-08-00143],[@B44-jcm-08-00143],[@B45-jcm-08-00143],[@B46-jcm-08-00143],[@B47-jcm-08-00143],[@B48-jcm-08-00143],[@B49-jcm-08-00143],[@B50-jcm-08-00143],[@B51-jcm-08-00143],[@B52-jcm-08-00143],[@B53-jcm-08-00143],[@B54-jcm-08-00143],[@B55-jcm-08-00143],[@B56-jcm-08-00143],[@B57-jcm-08-00143],[@B58-jcm-08-00143],[@B59-jcm-08-00143],[@B60-jcm-08-00143],[@B61-jcm-08-00143],[@B62-jcm-08-00143],[@B63-jcm-08-00143],[@B64-jcm-08-00143],[@B65-jcm-08-00143],[@B66-jcm-08-00143],[@B67-jcm-08-00143],[@B68-jcm-08-00143],[@B69-jcm-08-00143],[@B70-jcm-08-00143],[@B71-jcm-08-00143],[@B72-jcm-08-00143],[@B73-jcm-08-00143]\]. To estimate the incidence of CLS for the relevant groups, we presented the data with median (ranges) and also performed a meta-analysis to estimate the summary effects with proportion of CLS and 95% confidence interval (CI) using random-effect models \[[@B74-jcm-08-00143],[@B75-jcm-08-00143]\]. Random effects meta-analysis provides the weighted average of the effect sizes of a group of studies with the assumption that individual studies are estimating different effects \[[@B76-jcm-08-00143]\]. We evaluated the between-study heterogeneity using the *I*^2^ metric of inconsistency and P value of the χ^2^-based Cochran Q test. *I*^2^ is the ratio of the between-study variance over the sum of the within-study and between-study variances, and it ranges between 0--100%. *I*^2^ values of \<25%, 25--50%, and \>75% are usually judged to represent low, moderate (large), and high (very large) heterogeneity, respectively \[[@B77-jcm-08-00143]\]. Since statistical tests for heterogeneity are not very powerful, a higher *p* value than usual (*p* \< 0.10: significant heterogeneity) is used as the cut-off for clinical heterogeneity \[[@B78-jcm-08-00143]\].

2.4. Statistical Analysis {#sec2dot4-jcm-08-00143}
-------------------------

To meta-analyze the incidence of CLS according to the causative anti-cancer drugs or after BMT, the summary effects with 95% CI and the between-study heterogeneity were analyzed by using MedCalc version 15.8 software (MedCalc Software, Ostend, Belgium).

3. Results {#sec3-jcm-08-00143}
==========

There were 62 clinical trials (or studies) that reported on the incidence of CLS in patients receiving anti-cancer treatments or after BMT. Most of these studies were clinical trials in which the incidence of CLS was reported as an adverse event of anti-cancer treatment ([Table 1](#jcm-08-00143-t001){ref-type="table"}) \[[@B12-jcm-08-00143],[@B13-jcm-08-00143],[@B14-jcm-08-00143],[@B15-jcm-08-00143],[@B16-jcm-08-00143],[@B17-jcm-08-00143],[@B18-jcm-08-00143],[@B19-jcm-08-00143],[@B20-jcm-08-00143],[@B21-jcm-08-00143],[@B22-jcm-08-00143],[@B23-jcm-08-00143],[@B24-jcm-08-00143],[@B25-jcm-08-00143],[@B26-jcm-08-00143],[@B27-jcm-08-00143],[@B28-jcm-08-00143],[@B29-jcm-08-00143],[@B30-jcm-08-00143],[@B31-jcm-08-00143],[@B32-jcm-08-00143],[@B33-jcm-08-00143],[@B34-jcm-08-00143],[@B35-jcm-08-00143],[@B36-jcm-08-00143],[@B37-jcm-08-00143],[@B38-jcm-08-00143],[@B39-jcm-08-00143],[@B40-jcm-08-00143],[@B41-jcm-08-00143],[@B42-jcm-08-00143],[@B43-jcm-08-00143],[@B44-jcm-08-00143],[@B45-jcm-08-00143],[@B46-jcm-08-00143],[@B47-jcm-08-00143],[@B48-jcm-08-00143],[@B49-jcm-08-00143],[@B50-jcm-08-00143],[@B51-jcm-08-00143],[@B52-jcm-08-00143],[@B53-jcm-08-00143],[@B54-jcm-08-00143],[@B55-jcm-08-00143],[@B56-jcm-08-00143],[@B57-jcm-08-00143],[@B58-jcm-08-00143],[@B59-jcm-08-00143],[@B60-jcm-08-00143],[@B61-jcm-08-00143],[@B62-jcm-08-00143],[@B63-jcm-08-00143],[@B64-jcm-08-00143],[@B65-jcm-08-00143],[@B66-jcm-08-00143],[@B67-jcm-08-00143],[@B68-jcm-08-00143],[@B69-jcm-08-00143],[@B70-jcm-08-00143],[@B71-jcm-08-00143],[@B72-jcm-08-00143],[@B73-jcm-08-00143]\]. Among these, six studies reported on CLS associated with BMT with or without other agents ([Table 2](#jcm-08-00143-t002){ref-type="table"}) \[[@B40-jcm-08-00143],[@B42-jcm-08-00143],[@B70-jcm-08-00143],[@B71-jcm-08-00143],[@B72-jcm-08-00143],[@B73-jcm-08-00143]\]. The results of meta-analyses on the incidence of CLS induced by various drugs in cancer patients are summarized in [Table 3](#jcm-08-00143-t003){ref-type="table"} and [Supplementary Figure S1a--n](#app1-jcm-08-00143){ref-type="app"}.

There were 18 studies that reported on the incidence of CLS associated with the use of interleukin-2 (IL-2), which ranged from 5.3% to 100%. The incidence of CLS by IL-2 was 34.7% by overall estimation and 43.9% by meta-analysis. Although varying treatment doses were used, no correlations were found between the dose of IL-2 and the overall incidence of CLS. IL-2 was used in combination with other agents in several studies. These included combinations with bevacizumab (one study), imatinib mesylate (one study, three dose-related results), taurolidine (one study), interferon (IFN)-alpha (two studies), chimeric human/murine anti-GD2 ch14.18 monoclonal antibody (mAb) (one study), granulocyte-macrophage colony-stimulating factor (GM-CSF) + granulocyte colony-stimulating factor (G-CSF) (one study), GM-CSF + anti-GD2 mAb + isotretinoin (one study) and 5-fluorouracil (5-FU) (two studies). The incidence of CLS in patients treated with IL-2 with other agents was 29.1% by overall estimation and 32.0% by meta-analysis. We found that the highest incidence of CLS (80.5% and 100%) was observed when IL-2 was combined with IFN-alpha. In the IL-2 + imatinib mesylate group, there was a dose-related increase in the incidence of CLS (0% → 9% → 33.3%). The incidence of CLS in patients who received IL-2 + bevacizumab (IL-2 dose: 9 μg/kg) was 100%. In cases with concomitant IL-2 + 5-FU treatment, the incidence of CLS varied from 6.3% to 25.0%, resulting in 17.5% by overall estimation and 17.1% by meta-analysis.

Two studies reported on the incidence of CLS associated with the use of IL-1 in combination with carboplatin (one study, 40% CLS incidence) or etoposide (one study, 44.4%). Three studies reported on the incidence of CLS associated with the use of GM-CSF, which ranged from 6.8% to 15.0%. The incidence of CLS in patients treated with GM-CSF was low (9.0%) by overall estimation and 10.1% by meta-analysis. The incidence of CLS by GM-CSF was 9.0% by overall estimation and 10.1% by meta-analysis.

Three studies reported on the incidence of CLS associated with the use of gemcitabine, which was very low (2.8--4.3%). The incidence of CLS caused by gemcitabine was 3.5% by overall estimation and 4.9% by meta-analysis. There were two studies that reported on the incidence of CLS associated with the use of SS1P (recombinant anti-mesothelin immunotoxin), which was 5.9% and 54.2%, and showed no dose-response.

Thirteen studies reported on the incidence of CLS associated with the use of various kinds of anti-cluster of differentiation (CD) agents, which ranged from 5.9% to 100%. The incidence of CLS by various kinds of anti-CD agents was 33.9% by overall estimation and 35.6% by meta-analysis. There were four studies that reported on the incidence of CLS associated with the use of anti-CD22 mAb, which ranged from 11.5% to 100%. The incidence of CLS by various kinds of anti-CD22 mAb was 40.7% by overall estimation and 48.1% by meta-analysis. It appeared that there was an increasing incidence of CLS with an increasing treatment dose of anti-CD22 mAb. The addition of anti-CD19 mAb to anti-CD22 mAb treatment did not result in a further increase in the incidence of CLS. Three studies reported on the incidence of CLS associated with the use of anti-CD25, which ranged from 6.7% to 100%. The incidence of CLS by various kinds of anti-CD25 was 36.7% by overall estimation and 42.2% by meta-analysis.

There were single studies reporting on other drugs associated with CLS in cancer patients, with an incidence of CLS ranging from 3.4% to 80%. The incidence of CLS was high with the use of pyrrolobenzodiazepine (one study, 62.5%), paclitaxel (one study, 80.0%), and moderate with the use of anti-B4-bR (B-cell restricted immunotoxin anti-B4-blocked ricin) (one study, 41.7%), FK973 (novel, substituted dihydro benzoxazine structurally similar to mitomycin) (one study, 35.3%), and low with the use of SGN-10 (a single-chain immunotoxin) (one study, 2.2%), clofarabine + cytarabine + liposomal daunorubicin (one study, 3.4%), cyclosporine (one study, 8.3%), dihydro benzoxazine (one study, 11.1%), ABR-217620 (naptumomab estafenatox) (one study, 15.4%), and ricin A chain-containing immunotoxin (one study, 21.4%).

There were seven studies reporting the incidence of CLS associated with BMT with or without other agents, which ranged from 6.8% to 52.7%. The incidence of CLS associated with BMT was 21.1% by overall estimation and 21.7% by meta-analysis ([Table 2](#jcm-08-00143-t002){ref-type="table"} and [Table 3](#jcm-08-00143-t003){ref-type="table"}, [Supplementary Figure S1o](#app1-jcm-08-00143){ref-type="app"}).

4. Discussion {#sec4-jcm-08-00143}
=============

CLS is an important medical condition that is characterized by the escape of blood plasma into the interstitial space, resulting in edema, hypoalbuminemia, hemoconcentration, and low blood pressure \[[@B2-jcm-08-00143]\]. The pathogenesis of secondary CLS due to anti-cancer treatment is not well-known, but there are several studies supporting the role of pathogenic molecules of idiopathic CLS including multiple cytokines, angiopoietin-2, and vascular endothelial growth factor (VEGF) \[[@B5-jcm-08-00143],[@B10-jcm-08-00143],[@B79-jcm-08-00143],[@B80-jcm-08-00143]\], although the pathophysiology of idiopathic and secondary CLS may be somewhat different, because CLS by anti-cancer drugs could also develop due to a direct toxicity to the capillary system. These molecules are mostly related to an increase in the permeability of vascular endothelial cells leading to vascular leakage. Especially, multiple animal studies suggest that IL-2 causes the acute injury of normal tissues by enhancing neutrophil adhesion and generating reactive oxygen intermediates, proteases, and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF alpha), which can cause a vascular leakage \[[@B81-jcm-08-00143],[@B82-jcm-08-00143]\]. The proposed pathogenesis of CLS is demonstrated in [Figure 2](#jcm-08-00143-f002){ref-type="fig"}.

Evaluating the incidence of CLS is challenging because the clinical presentations of CLS are non-specific, and it is expected that cases have been misdiagnosed in the past. Recently, CLS has been increasingly diagnosed due to increased awareness of the disease \[[@B4-jcm-08-00143]\]. CLS due to anti-cancer drugs has been sporadically reported in the literature, and it has recently been registered in VigiBase (<http://www.vigiaccess.org/>), the World Health Organization global Individual Case Safety Report (ICSR) database, which contains reports of suspected adverse drug reactions (ADRs) collected by national drug authorities in more than 130 countries between 1967 and February 2018 \[[@B10-jcm-08-00143]\]. However, it did not report the incidence rate of CLS for patients treated with anti-cancer drugs, and our study firstly reported the incidence of CLS according to the drugs or after BMT by meta-analysis.

Due to the lack of an overall understanding of CLS as an adverse effect of anti-cancer treatment, we carried out a systematic analysis of published clinical trials (or studies) to evaluate the incidence of anti-cancer treatment-related CLS. Through calculating the number of CLS among total patients reported in clinical trials (or studies), we were able to estimate the pooled incidence of CLS when patients were treated with several anti-cancer treatment-related drugs and after BMT. The most studied drug was IL-2, which was used as a cancer immunotherapy, and the incidence of CLS was 34.7% by overall estimation, suggesting that it may be a common adverse effect, and that the phenomenon of CLS has been underestimated in cancer patients in the past. In addition, the incidence of CLS in cancer patients differed according to the specific drug or drug combinations that were used and ranged from 5.3% to 100.0%. Therefore, our analysis shows important results that oncologists should be aware of. However, these studies did not report on the treatment strategies or clinical outcome of CLS, because most studies reported CLS as an adverse event of the drug. The clinical and laboratory data, treatment modalities, and mortality rate of patients and contributing factors leading to mortality of CLS in cancer are well analyzed in our recent systematic review of sporadic case reports \[[@B4-jcm-08-00143]\].

We also found that BMT may be an important risk factor for CLS in cancer patients. The incidence of CLS associated with BMT with or without other agents ranged from 6.8% to 52.7%. The pathophysiology of CLS in BMT-related CLS has not been fully studied, but some hypotheses on the contributing factors have been suggested such as pivotal contribution by circulating leukocytes, decreased C1 esterase inhibitor activity, elevated C4d concentrations, the use of G-CSF or GM-CSF, and elevation of terminal complement complex (TCC) levels \[[@B70-jcm-08-00143],[@B71-jcm-08-00143],[@B72-jcm-08-00143],[@B73-jcm-08-00143]\]. Future studies in this area may shed light on the pathophysiology of CLS associated with BMT and trigger the development of novel therapeutic approaches.

Besides IL-2 and BMT, we identified several potential causative drugs of CLS. The overall estimation of CLS incidence by causative drugs varied from 3.5% (gemcitabine, three studies) to 100% (IL-2 + bevacizumab, one study). Studies with IL-2 + bevacizumab (one study, 100%) and IL-2 + IFN-alpha 2a (two studies, overall estimation 85.5%, meta-analysis 90.4%) showed relatively high CLS incidence proportions, while studies with gemcitabine (three studies, overall estimation 3.5%, meta-analysis 4.9%) and GM-CSF (three studies, overall estimation 9.0%, meta-analysis 10.1%) showed low incidence. Likewise, anti-cancer agents, including IL-2 + imatinib mesylate (three studies) and anti-CD22 mAb (four studies) showed a dose-dependent increase in the incidence of CLS. Considering the small number of studies, it is difficult to state whether there are dose-related trends for these agents. Further studies should be performed to clarify this relationship in order to establish comprehensive therapeutic guidelines, taking CLS as an adverse effect into account.

Several limitations of this study should be considered. First, the studies that we included were not placebo-controlled trials with a control arm that would allow defining how much of the CLS was attributable to treatment rather than the type and severity of the treated condition. Since the included individual studies just reported the number of CLS as an adverse event of anti-cancer drugs, the prognosis and long-term outcome of CLS could not be addressed. Therefore, further clinical trials or observational studies should attempt to address the prospective associations between CLS and anti-cancer treatment. Second, coexisting conditions were not considered in our study. For example, we extracted the name of the causative drug and its dose, but other effects such as drug combination or cumulative effects may have affected the outcomes. Also, there might be other causes for CLS besides anti-cancer treatment, so potential confounders should be acknowledged.

5. Conclusions {#sec5-jcm-08-00143}
==============

Our study is the first systematic analysis of the incidence of CLS in cancer patients treated with various anti-cancer agents and therapy. The incidence of CLS due to IL-2 (18 studies) was 34.7% by overall estimation and 43.9% by meta-analysis, and the corresponding figures for BMT were 21.1% and 21.7%, respectively CLS was also reported in cases receiving other agents. Our study results highlight the need for inclusion of the risk of development of CLS in the choice of treatment and preparation of the appropriate management for cancer patients in anticipation of this syndrome. Thus, we recommend that physicians and oncologists should be aware of secondary CLS in cancer patients during anti-cancer treatment, and encourage careful observation to prevent CLS or enable timely management when CLS develops.

The following are available online at <http://www.mdpi.com/2077-0383/8/2/143/s1>, Table S1: Checklist summarizing compliance with PRISMA guidelines, Figure S1: Forest plot of meta-analysis to estimate the incidence of capillary leak syndrome according to various anti-cancer treatments.

###### 

Click here for additional data file.

J.I.S. and J.H.O. designed the study. J.H.O., I.R.L., K.H.L., J.W.S. and J.I.S. collected the data and J.I.S. did the analysis. G.H.J., J.I.S., M.E., D.W.K., H.J.v.d.V., A.K., O.A.R., B.S., M.S., N.V., E.D., A.K. and J.R. wrote the first draft of the manuscript and gave critical comments on manuscript draft. All authors had full access to all the study data. All authors reviewed, wrote and approved the final version. The corresponding author had final responsibility for the decision to submit for publication.

The authors declare no conflict of interest.

![Flow chart of literature search. CLS: Capillary leak syndrome, G-CSF: Granulocyte colony-stimulating factor.](jcm-08-00143-g001){#jcm-08-00143-f001}

![The proposed pathogenesis of capillary leak syndrome (CLS). Some pathogenic molecules in CLS show increased levels in sera, which triggers endothelial cell damage and plasma leakage from vessels. This is supposed to eventually result in the classic triad of symptoms (hypoalbuminemia, hemoconcentration, and hypotension) and normal tissue damages. VEGF: vascular endothelial growth factor, IL: Interleukin, TNF: Tumor necrosis factor, IFN: Interferon, ET: endothelin, CCL: chemokine ligand, Ang2: angiopoietin-2.](jcm-08-00143-g002){#jcm-08-00143-f002}

jcm-08-00143-t001_Table 1

###### 

Summary profiles of clinical trials that reported capillary leak syndrome as an adverse event of anti-cancer drugs.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref. No.                     Author, Year of Publication   Period of Study   Country                  Total Number   CLS    Incidence (%)   Diagnosis                                                                                                                                                                                             Drug                                                             Treatment Dose
  ---------------------------- ----------------------------- ----------------- ------------------------ -------------- ------ --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  **IL-2**                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B12-jcm-08-00143]\]      Atkins et al., 1999           1985--1993        USA                      270            92     34.1            Melanoma                                                                                                                                                                                              IL-2                                                             720,000 IU/kg every 8 h

  \[[@B13-jcm-08-00143]\]      Sparano et al., 1993          1988--1992        USA                      44             40     90.9            Melanoma                                                                                                                                                                                              IL-2                                                             6 × 10^6^IU/m^2^ every 8 h

  \[[@B14-jcm-08-00143]\]      Tarhini et al., 2007          2000--2003        USA                      26             7      26.9            Melanoma                                                                                                                                                                                              IL-2                                                             600,000 IU/kg every 8 h for up to 14 doses for 2 cycles

  \[[@B15-jcm-08-00143]\]      Talpur et al., 2012           2003--2008        USA                      8              6      75.0            Cutaneous peripheral T-cell lymphoma                                                                                                                                                                  IL-2                                                             Dose level 18 μg/kg

  \[[@B16-jcm-08-00143]\]      Gallagher et al, 2007         2006              Israel                   14             14\*   100.0           Melanoma, renal cell carcinoma                                                                                                                                                                        IL-2                                                             Dose level 8--14 μg/kg

  \[[@B17-jcm-08-00143]\]      Shusterman et al., 2010       NA                USA                      39             12     30.8            Neuroblastoma                                                                                                                                                                                         IL-2                                                             Dose level 12 mg/m^2^

  \[[@B18-jcm-08-00143]\]      Shaughnessy et al., 2005      NA                USA                      2              1      50.0            Non-Hodgkin lymphoma, Hodgkin disease, acute leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, multiple myeloma, aplastic anemia                                                      IL-2                                                             Dose level 9.0 μg/kg

  \[[@B18-jcm-08-00143]\]      Shaughnessy et al., 2005      NA                USA                      20             2      10.0            Non-Hodgkin lymphoma, Hodgkin disease, acute leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, multiple myeloma, aplastic anemia                                                      IL-2                                                             Dose level 4.5 μg/kg

  \[[@B19-jcm-08-00143]\]      Frankel et al., 2003          NA                USA                      18             2      11.1            Chronic lymphocytic leukemia                                                                                                                                                                          IL-2                                                             Dose level 9 or 18 μg/kg

  \[[@B20-jcm-08-00143]\]      Duvic et al., 2002            NA                USA                      71             18     25.4            Cutaneous T-cell lymphoma                                                                                                                                                                             IL-2                                                             Dose level 9 or 18 μg/kg

  \[[@B21-jcm-08-00143]\]      Foss et al., 2001             NA                USA                      15             2      13.3            Cutaneous T-cell lymphoma                                                                                                                                                                             IL-2                                                             Dose level 9 or 18 μg/kg

  \[[@B22-jcm-08-00143]\]      Sievers et al., 2000          NA                USA                      60             7      11.7            Acute myelogenous leukemia                                                                                                                                                                            IL-2                                                             9,000,000 IU/m^2^ for 4 days and 16,000,000 IU/m^2^for 10 days

  \[[@B23-jcm-08-00143]\]      Duvic et al., 1998            NA                USA                      4              1      25.0            Cutaneous T cell lymphoma                                                                                                                                                                             IL-2                                                             Dose level 9 or 18 μg/kg

  \[[@B24-jcm-08-00143]\]      Meehan et al., 1997           1993--1995        USA                      57             3      5.3             Breast cancer                                                                                                                                                                                         IL-2                                                             MTD 6 × 10^6^IU/m^2^/day

  \[[@B25-jcm-08-00143]\]      Chang et al., 1993            NA                Japan                    20             15     75.0            Melanoma, renal cell cancer                                                                                                                                                                           IL-2                                                             Using vaccine-primed lymph node cell with IL-2 (180,000 IU/kg)

  \[[@B26-jcm-08-00143]\]      van Haelst Pisani C\          NA                France                   5              4      80.0            Melanoma, renal cell cancer                                                                                                                                                                           IL-2                                                             Human recombinant IL-2 3 × 10⁶ IU/m²/24 h for 4 or 5 days
                               et al., 1991                                                                                                                                                                                                                                                                                                                                                                          

  \[[@B27-jcm-08-00143]\]      Philip et al., 1989           1987--1988        France                   20             8      40.0            Renal cell cancer                                                                                                                                                                                     IL-2                                                             IL-2 3 × 10⁶ IU/m² with lymphapheresis(17), IL-2 3 × 10 ⁶IU/m²(3)

  \[[@B28-jcm-08-00143]\]      Carey et al., 1997            NA                UK                       10             10\*   100.0           Malignant melanoma, renal cell cancer                                                                                                                                                                 IL-2                                                             Using 3 × 10⁶ IU/m²/day for 5 days

  **IL-2 with other agents**                                                                                                                                                                                                                                                                                                                                                                                         

  \[[@B16-jcm-08-00143]\]      Gallagher et al., 2007        2006              Israel                   4              4      100.0           Renal cell carcinoma                                                                                                                                                                                  IL-2\                                                            IL-2 dose level 9--14 μg/kg
                                                                                                                                                                                                                                                                                                                                                    + bevacizumab                                                    

  \[[@B29-jcm-08-00143]\]      Pautier et al., 2013          NA                France                   3              0      0.0             Melanoma, ovarian adenocarcinoma, Merkel-cell carcinoma, gastrointestinal stromal tumor, rectal adenocarcinoma, cervical adenocarcinoma                                                               IL-2\                                                            IL-2: 3,000,000 IU/day, imatinib mesylate 400 mg/day
                                                                                                                                                                                                                                                                                                                                                    + imatinib mesylate                                              

  \[[@B29-jcm-08-00143]\]      Pautier et al., 2013          NA                France                   11             1      9.0             Melanoma, ovarian adenocarcinoma, Merkel-cell carcinoma, gastrointestinal stromal tumor, rectal adenocarcinoma, cervical adenocarcinoma                                                               IL-2\                                                            IL-2: 6,000,000 IU/day, imatinib mesylate 400 mg/day
                                                                                                                                                                                                                                                                                                                                                    + imatinib mesylate                                              

  \[[@B29-jcm-08-00143]\]      Pautier et al., 2013          NA                France                   3              1      33.3            Melanoma, ovarian adenocarcinoma, Merkel-cell carcinoma, gastrointestinal stromal tumor, rectal adenocarcinoma, cervical adenocarcinoma                                                               IL-2\                                                            IL-2: 9,000,000 IU/day, imatinib mesylate 400 mg/day
                                                                                                                                                                                                                                                                                                                                                    + imatinib mesylate                                              

  \[[@B30-jcm-08-00143]\]      O'Brien et al., 2006          NA                Ireland                  10             0      0.0             Melanoma                                                                                                                                                                                              IL-2\                                                            IL-2 72 MIU/m^2^ for 120 h\
                                                                                                                                                                                                                                                                                                                                                    + taurolidine                                                    Taurolidine 2% w/v via continuous infusion

  \[[@B31-jcm-08-00143]\]      Pichert et al., 1991          1988--1989        Switzerland              14             14\*   100.0           Renal cell carcinoma, melanoma                                                                                                                                                                        IL-2\                                                            IL-2 3 MIU/m^2^ for 4 days\
                                                                                                                                                                                                                                                                                                                                                    + IFN-alfa 2a                                                    IFN-alpha 6 MIU/m^2^ for 2 days (1, 4 day)

  \[[@B13-jcm-08-00143]\]      Sparano et al., 1993          1988--1992        USA                      41             33     80.5            Melanoma                                                                                                                                                                                              IL-2\                                                            IL-2 4.5 × 10^6^IU/m^2^ per dose\
                                                                                                                                                                                                                                                                                                                                                    + IFN-alfa                                                       IFN-alpha 2 4.5 × 10^6^IU/m^2^

  \[[@B32-jcm-08-00143]\]      Gilman et al., 2009           1997--2002        USA                      19             3      15.8            Neuroblastoma                                                                                                                                                                                         IL-2 + ch14.18                                                   Ch14.18 20 and 40 mg/m^2^/day\
                                                                                                                                                                                                                                                                                                                                                                                                                     IL-2 4.5 × 10^6^IU/m^2^/day

  \[[@B33-jcm-08-00143]\]      Meehan et al., 2010           NA                USA                      12             2      16.7            Multiple myeloma, non-Hodgkin\                                                                                                                                                                        IL-2 + GM-CSF + G-CSF                                            IL-2 6 × 10^5--^1.5 × 10^6^IU/m^2^\
                                                                                                                                              lymphoma                                                                                                                                                                                                                                                               G-CSF 5 μg/kg\
                                                                                                                                                                                                                                                                                                                                                                                                                     GM-CSF 7.5 μg/kg

  \[[@B34-jcm-08-00143]\]      Yu et al., 2010               2001--2009        USA                      226            51     22.6            Neuroblastoma                                                                                                                                                                                         IL-2\                                                            IL-2 3.0 × 10^6^IU/m^2^ (week 1), 4.5 × 10^6^IU/m^2^ (week 2)\
                                                                                                                                                                                                                                                                                                                                                    + GM-CSF\                                                        GM-CSF 250 μg/m^2^\
                                                                                                                                                                                                                                                                                                                                                    + anti-GD2\                                                      isotretionoin 160mg/m^2^
                                                                                                                                                                                                                                                                                                                                                    + isotretionoin                                                  

  \[[@B35-jcm-08-00143]\]      Hamblin et al., 1993          1988--1989        UK                       16             1      6.3             Metastatic colorectal cancer                                                                                                                                                                          IL-2 + 5-FU                                                      IL-2 18 × 10 IU/m^2^/day over 120 h\
                                                                                                                                                                                                                                                                                                                                                                                                                     5FU 600 mg/m^2^

  \[[@B36-jcm-08-00143]\]      Savage et al., 1997           NA                UK                       24             6      25.0            Metastatic renal cancer                                                                                                                                                                               IL-2 + 5-FU                                                      IL-2 9 × 10^6^IU\
                                                                                                                                                                                                                                                                                                                                                                                                                     5-FU 200 mg/m^2^

  **IL-1 with other agents**                                                                                                                                                                                                                                                                                                                                                                                         

  \[[@B37-jcm-08-00143]\]      Smith et al., 1993            1990--1992        USA                      15             6      40.0            Colon cancer, melanoma, renal cell cancer, lung cancer, pancreatic cancer, liposarcoma, adenocarcinoma with unknown primary site                                                                      IL-1 alpha + carboplatin                                         IL-1 alpha 0.03, 0.1, 0.3 μg/kg\
                                                                                                                                                                                                                                                                                                                                                                                                                     carboplatin 800 mg/m^2^

  \[[@B38-jcm-08-00143]\]      Worth et al., 1997            1994              USA                      9              4      44.4            Osteosarcoma                                                                                                                                                                                          IL-1 alpha + etoposide                                           IL-1 alpha 0.1 *μ*g/kg\
                                                                                                                                                                                                                                                                                                                                                                                                                     etoposide 100 mg/m^2^

  **IL-4**                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B39-jcm-08-00143]\]      Sosman et al., 1994           NA                USA                      17             2      11.8            Renal cell carcinoma, melanoma, colon carcinoma, cholangiocarcinoma                                                                                                                                   IL-4+IL-2                                                        IL-4 40--600 μg /m^2^/day\
                                                                                                                                                                                                                                                                                                                                                                                                                     IL-2 11.2 MIU/m^2^/day

  **GM-CSF**                                                                                                                                                                                                                                                                                                                                                                                                         

  \[[@B40-jcm-08-00143]\]      Gorin et al., 1992            1988--1990        France                   44             3      6.8             Non-Hodgkin lymphoma                                                                                                                                                                                  GM-CSF                                                           Dose level 250 μg/m^2^

  \[[@B41-jcm-08-00143]\]      Liberati et al., 1991         NA                Italy                    14             1      7.1             Non-Hodgkin lymphoma                                                                                                                                                                                  GM-CSF                                                           Dose level 5 μg/kg

  \[[@B42-jcm-08-00143]\]      Steward et al., 1989          NA                USA &UK                  20             3      15.0            Metastatic solid tumors                                                                                                                                                                               GM-CSF                                                           Using dose 0.3, 1.0, 3.0, 10, 30, and 60 μg/kg/day\
                                                                                                                                                                                                                                                                                                                                                                                                                     Dose level 32 μg /kg

  **Gemcitabine**                                                                                                                                                                                                                                                                                                                                                                                                    

  \[[@B43-jcm-08-00143]\]      Jidar et al., 2009            NA                France                   23             1      4.3             Cutaneous T-cell lymphoma                                                                                                                                                                             Gemcitabine                                                      Using dose 700--1000 mg/m^2^

  \[[@B44-jcm-08-00143]\]      Kurosaki et al., 2009         2003--2006        Japan                    27             1      3.7             Pancreatic cancer                                                                                                                                                                                     Gemcitabine                                                      Dose level 1000 mg/m^2^ biweekly

  \[[@B45-jcm-08-00143]\]      Dumontet et al., 2001         1988--2000        France                   36             1      2.8             Non-Hodgkin lymphoma                                                                                                                                                                                  Gemcitabine                                                      Dose level 1 g/m^2^

  **SS1P**                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B46-jcm-08-00143]\]      Kreitman et al., 2009         NA                USA                      24             13     54.2            Peritoneal mesothelioma, pleural mesothelioma, pleural--peritoneal mesothelioma, ovarian carcinoma, pancreatic carcinoma                                                                              SS1P                                                             Dose level 4--25 μg/kg

  \[[@B47-jcm-08-00143]\]      Hassan et al., 2007           2000--2006        USA                      34             2      5.9             Peritoneal mesothelioma, pleural mesothelioma, pleural--peritoneal mesothelioma, ovarian carcinoma, pancreatic carcinoma                                                                              SS1P                                                             Dose level 18 or 25 μg/kg

  **Anti-CD agents**                                                                                                                                                                                                                                                                                                                                                                                                 

  \[[@B48-jcm-08-00143]\]      Sausville et al., 1995        NA                USA                      11             4      36.4            B-cell lymphoma                                                                                                                                                                                       Anti-CD22                                                        Dose level 28.8 mg/m^2^\
                                                                                                                                                                                                                                                                                                                                                                                                                     MTD 19.2 mg/m^2^

  \[[@B49-jcm-08-00143]\]      Vitetta et al., 1991          NA                USA                      15             15\*   100.0           B-cell lymphoma                                                                                                                                                                                       Anti-CD22                                                        Using dose 12.5, 25, 50, 75, 100 mg/m^2^

  \[[@B50-jcm-08-00143]\]      Wayne et al., 2014            NA                USA                      7              2      28.6            Acute lymphoblastic leukemia                                                                                                                                                                          Anti-CD22                                                        Dose level 30 μg/kg

  \[[@B51-jcm-08-00143]\]      Amlot et al., 1993            NA                USA                      26             3      11.5            B-cell lymphoma                                                                                                                                                                                       Anti-CD22                                                        Using Maximal single dose 2.5--13.9 mg/m^2^

  \[[@B52-jcm-08-00143]\]      Stathis et al., 2014          NA                Switzerland              5              1      20.0            Non-Hodgkin lymphoma                                                                                                                                                                                  Anti-CD22 + temsirolimus                                         Using dose Anti-CD22 0.8 mg/m^2^+ temsirolimus 15 mg/day,\
                                                                                                                                                                                                                                                                                                                                                                                                                     Anti-CD22 0.8 mg/m^2^ + temsirolimus 10 mg/day

  \[[@B53-jcm-08-00143]\]      Schindler et al., 2011        NA                USA                      17             1      5.9             B-cell acute lymphoblastic leukemia                                                                                                                                                                   Anti-CD19 + anti-CD22                                            Dose level 8 mg/m^2^

  \[[@B54-jcm-08-00143]\]      Bachanova et al., 2015        NA                USA                      25             7      28.0            Pre-B acute lymphoblastic leukemia, chronic lymphocytic leukemia, Non-Hodgkin lymphoma                                                                                                                Anti-CD19 + anti-CD22                                            Dose level 40--60 μg/kg

  \[[@B55-jcm-08-00143]\]      Schnell et al., 2003          NA                Germany                  27             3      11.1            Hodgkin lymphoma                                                                                                                                                                                      Anti-CD25                                                        Dose level 15--20 mg/m^2^

  \[[@B56-jcm-08-00143]\]      Schnell et al., 2000          NA                Germany                  18             18\*   100.0           Hodgkin lymphoma                                                                                                                                                                                      Anti-CD25                                                        Dose level 15 mg/m^2^/cycle

  \[[@B57-jcm-08-00143]\]      Engert et al., 1997           NA                Germany                  15             1      6.7             Hodgkin lymphoma                                                                                                                                                                                      Anti-CD25                                                        Dose level 5 mg/m^2^(3), 10 mg/m^2^(3), 15 mg/m^2^(6), 20 mg/m^2^(3)

  \[[@B58-jcm-08-00143]\]      Schnell et al., 2002          NA                Germany                  17             3      17.6            Hodgkin lymphoma, Non-Hodgkin lymphoma                                                                                                                                                                Anti-CD30                                                        Dose level 7.5 mg/m^2^(1), 10 mg/m^2^(2)\
                                                                                                                                                                                                                                                                                                                                                                                                                     MTD 5 mg/m^2^

  \[[@B59-jcm-08-00143]\]      Stone et al., 1996            NA                USA                      23             16     69.6            Non-Hodgkin lymphoma                                                                                                                                                                                  Anti-CD19\                                                       MTD 19.2 mg/m^2^
                                                                                                                                                                                                                                                                                                                                                    + IgG-HD37-dgA                                                   

  \[[@B60-jcm-08-00143]\]      Uckun et al., 1999            1996--1998        USA                      15             1      6.7             Acute lymphoblastic leukemia, chronic lymphocytic leukemia                                                                                                                                            CD19 receptor directed tyrosine kinase inhibitor B43-Genistein   Dose level 0.1 mg/kg

  **Other agents**                                                                                                                                                                                                                                                                                                                                                                                                   

  \[[@B61-jcm-08-00143]\]      Baluna et al., 1996           NA                USA                      56             12     21.4            Non-Hodgkin lymphoma                                                                                                                                                                                  Ricin A chain-containing immunotoxin                             Using IgG-HD37-RTA continuous infusion 9.6--19.2 mg/m^2^(2), bolus infusion range 2--24 mg/m^2^(2)\
                                                                                                                                                                                                                                                                                                                                                                                                                     IgG-RFB4-RTA continuous infusion 9.6--28.8 mg/m^2^(4), bolus infusion 23--48 mg/m^2^(2)\
                                                                                                                                                                                                                                                                                                                                                                                                                     Fab'-RFB4-RTA bolus infusion 25--100 mg/m^2^(2)

  \[[@B62-jcm-08-00143]\]      Borghaei et al., 2009         NA                USA                      39             6      15.4            NSCLC, pancreatic cancer                                                                                                                                                                              ABR-217620                                                       Dose level 20 μg/kg

  \[[@B63-jcm-08-00143]\]      Hochhauser et al., 2009       2004--2006        UK                       16             10     62.5            Ampulla of vater cancer, cholangiocarcinoma, colorectal cancer, lung cancer, esophagus cancer, pancreatic cancer, sarcoma, malignant melanoma, stomach cancer                                         Pyrrolobenzodiazepine                                            Using dose 15--240 μg/m^2^

  \[[@B64-jcm-08-00143]\]      Posey et al., 2002            NA                USA                      46             1      2.2             Colorectal cancer, pancreatic cancer, ovarian cancer, breast cancer, lung cancer, prostate cancer, head and neck cancer, stomach cancer, endometrial cancer, thyroid cancer, unknown primary lesion   SGN-10\                                                          Dose level \> or = 0.384 mg/m^2^
                                                                                                                                                                                                                                                                                                                                                    (or BR96 sFv-PE40)                                               

  \[[@B65-jcm-08-00143]\]      Elias et al., 2001            NA                USA                      5              4      80.0            Breast cancer                                                                                                                                                                                         Paclitaxel                                                       Dose level 150 mg/m^2^

  \[[@B66-jcm-08-00143]\]      Grossbard et al., 1993        1990--1991        USA                      12             5      41.7            Non-Hodgkin lymphoma                                                                                                                                                                                  Anti-B4-bR                                                       Using dose 20, 40, 50 μg/kg/day for 7 days\
                                                                                                                                                                                                                                                                                                                                                                                                                     MTD 40 μg/kg

  \[[@B67-jcm-08-00143]\]      Pazdur et al., 1991           NA                USA                      17             6      35.3            Metastatic cancer                                                                                                                                                                                     FK973                                                            Using dose 30 mg/m^2^(2), 45 mg/m^2^(4)

  \[[@B68-jcm-08-00143]\]      Barrett et al., 1982          1980--1981        UK                       36             4      11.1            Acute myeloid leukemia, acute lymphoblastic leukemia, aplastic anemia, mucopolysaccharidosis, metachromic leukodystrophy                                                                              Dihydro benzoxazine                                              Using dose 12.5 mg/kg(10), 500 g/m^2^(26)

  \[[@B69-jcm-08-00143]\]      Zwaan et al., 2014            NA                Multicenter in Europe†   36             3      8.3             Acute myeloid leukemia                                                                                                                                                                                Cyclosporine                                                     Using dose plasma concentration \<100 μg/L

  \[[@B69-jcm-08-00143]\]      Zwaan et al., 2014            NA                Multicenter in Europe†   29             1      3.4             Acute myeloid leukemia                                                                                                                                                                                Clofarabine\                                                     Clofarabine 20, 30, 40 mg/m^2^\
                                                                                                                                                                                                                                                                                                                                                    + cytarabine\                                                    Ara-C 2 g/m^2^/day\
                                                                                                                                                                                                                                                                                                                                                    + liposomal daunorubicin                                         dauorubicin 40--60 mg/m^2^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available (information was not included in the case series article), CLS: capillary leak syndrome, Using dose: drug dose that was administered to patients, Dose level: serum drug level when the patients show toxicity, DLT: dose limited toxicity, IL: Interleukin, *w*/*v*: weight/volume percentage, ch14.18: a chimeric human/murine anti-GD2 antibody, MIU: million international units, GVHD: graft-versus-host disease, INF: interferon, GM-CSF: granulocyte-macrophage colony-stimulating factor, G-CSF: granulocyte-colony stimulating factor, 5-FU: 5-fluorouracil, SS1P: recombinant anti-mesothelin immunotoxin, CD: cluster of differentiation, MTD: maximum tolerated dose, NSCLC: Non small cell lung cancer, ABR-217620: naptumomab estafenatox, SGN-10: a single-chain immunotoxin, Anti-B4-bR: B-cell restricted immunotoxin anti-B4-blocked ricin, FK973: novel, substituted dihydro benzoxazine structurally similar to mitomycin, USA: United States of America, UK: United Kindom; \*All study patients developed capillary leak syndrome after receiving anti-cancer agents. There were no capillary leak syndrome features before treatment. † Study population was collected from multiple centers in Europe: Netherlands, Austria, Germany, France, the Czech Republic, and the United Kingdom.
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###### 

Summary profiles of clinical studies that reported capillary leak syndrome related to bone marrow transplantation.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref. No.                  Author, Year               Total\   CLS   Incidence\   Diagnosis                                              Hypothesis or Risk Factors
                                                       Number         (%)                                                                 
  ------------------------- -------------------------- -------- ----- ------------ ------------------------------------------------------ ----------------------------------------------------------------------------------------------------
  Only BMT related                                                                                                                        

  \[[@B70-jcm-08-00143]\]   Cahill, et al., 1996       55       29    52.7         Both allogeneic and autologous transplant recipients   Pivotal contribution by circulating leukocytes

  \[[@B71-jcm-08-00143]\]   Nurnberger, et al., 1993   12       4     33.3         Acute lymphoblastic leukemia\                          C1 Inhibitor activity decreased to 0.60-fold to 0.80-fold\
                                                                                   Aplastic anemia\                                       Elevated C4d concentrations (up to 2.4 mg/dL, upper normal threshold value: 0.9)
                                                                                   Fanconi's anemia\                                      
                                                                                   Neuroblastoma\                                         
                                                                                   Ewing's sarcoma\                                       
                                                                                   Lymphoepithelial carcinoma                             

  \[[@B72-jcm-08-00143]\]   Nurnberger, et al., 1997   96       20    20.8         Acute lymphoblastic leukemia\                          Receiving G-CSF or GM-CSF\*\
                                                                                   Acute myeloblastic leukemia\                           GVHD prophylaxis : MTX plus cyclosporine A\
                                                                                   Chronic myeloblastic leukemia\                         Allogeneic-related BMT, solid tumor\
                                                                                   Severe aplastic anemia\                                Unrelated BMT, hematologic disease\
                                                                                   Ewing tumors\                                          Patients with high-risk pretreatment
                                                                                   Rhabdomyosarcoma\                                      
                                                                                   Neuroblastoma\                                         
                                                                                   Lymphoepithelioma                                      

  \[[@B40-jcm-08-00143]\]   Gorin et al., 1992         44       3     6.8          Non-Hodgkin's lymphoma                                 BMT after using GM-CSF\* ( Dose level 250 μg/m^2^)

  \[[@B42-jcm-08-00143]\]   Steward et al., 1989       20       3     15.0         Metastatic solid tumors                                BMT after using GM-CSF\* (Using dose 0.3, 1.0, 3.0, 10, 30, and 60 μg/kg/day, dose level 32 μg/kg)

  \[[@B72-jcm-08-00143]\]   Nurnberger, et al., 1997   142      22    15.5         Acute lymphoblastic leukemia\                          BMT after using G-CSF\*\
                                                                                   Chronic myelomonocytic leukemia\                       Low levels of C1 esterase inhibitor†
                                                                                   Severe aplastic anemia\                                
                                                                                   Fanconi's anemia\                                      
                                                                                   Non-Hodgkin's lymphoma,\                               
                                                                                   Ewing tumor\                                           
                                                                                   Neuroblastoma\                                         
                                                                                   Rhabdomyosarcoma\                                      
                                                                                   Wiskott--Aldrich syndrome                              

  \[[@B73-jcm-08-00143]\]   Salat et al, 1995          48       7     14.6         Acute lymphoblastic leukemia\                          Elevation of terminal complement complex (TCC) levels\
                                                                                   Acute myeloblastic leukemia\                           Elevation of functional Cl-esterase inhibitor (CI-INH)\
                                                                                   Chronic myeloblastic leukemia\                         Elevation of Cl-inhibitor antigen (CI-INH antigen)
                                                                                   Hodgkin's lymphoma\                                    
                                                                                   Non-Hodgkin's lymphoma\                                
                                                                                   Severe aplastic anemia\                                
                                                                                   Multiple myeloma                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CLS: capillary leak syndome, GM-CSF: granulocyte-macrophage colony-stimulating factor, G-CSF: granulocyte-colony stimulating factor, GVHD: Graft-versus-host disease, MTX: methotrexate, BMT: bone marrow transplantation; \* These patients initially received bone marrow transplantation, and then received GM-CSF to correct neutropenia; † To correct this status, 15 severe CLS patients were treated with C1 INH concentrate using a cumulative dose of 180 units/kg in this article.
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###### 

Meta-analyses on the incidence of capillary leak syndrome induced by various anti-cancer drugs or after BMT in cancer patients.

  Causative Drugs            Numberof Studies   Total Number of Patients   Number of CLS   Incidence of CLS (Overall)   Incidence of CLS by Meta-Analysis (95%CI)   Heterogeneity I^2^ (*p* Value)   Incidence of CLS Median (Ranges)
  -------------------------- ------------------ -------------------------- --------------- ---------------------------- ------------------------------------------- -------------------------------- ----------------------------------
  IL-2                       18                 703                        244             34.7%                        43.9% (29.5--58.9)                          92.6% (*p* \< 0.0001)            32.4% (5.3--100)
  IL-2 with other agents     13                 405                        118             29.1%                        32.0% (15.6--51.1)                          91.1% (*p* \< 0.0001)            16.7% (0--100)
  IL-2 + IFN-alpha 2a        2                  55                         47              85.5%                        90.4% (64.1--100)                           80.0% (*p* = 0.0255)             90.3% (80.5--100)
  IL-2 + imatinib mesylate   3                  17                         2               11.8%                        15.0% (3.1--33.4)                           0% (*p* = 0.4889)                9.0% (0--33.3)
  IL-2 + bevacizumab         1                  4                          4               100.0%                       \-                                          \-                               \-
  IL-2 + 5-FU                2                  40                         7               17.5%                        17.1% (3.7--37.4)                           56.1% (*p* = 0.1312)             33.3% (6.3--25.0)
  IL-1 with other agents     2                  24                         10              41.7%                        42.3% (24.3--61.4)                          0% (*p* = 0.8266)                42.2% (40--44.4)
  IL-4 (+IL-2)               1                  17                         2               11.8%                        \-                                          \-                               \-
  GM-CSF                     3                  78                         7               9.0%                         10.1% (4.6--17.6)                           0% (*p* = 0.5802)                7.1% (6.8--15.0)
  Gemcitabine                3                  86                         3               3.5%                         4.9% (1.4--10.3)                            0% (*p* = 0.9273)                3.7% (2.8--4.3)
  SS1P                       2                  58                         15              25.9%                        26.9 (0.00--78.6)                           94.5% (*p* \< 0.0001)            30.1 (5.9--54.2)
  Anti-CD agents             13                 221                        75              33.9%                        35.6% (16.1--60.0)                          91.8% (*p* \< 0.0001)            20.0% (5.9--100)
  Anti-CD22                  4                  59                         24              40.7%                        48.1% (6.3--91.7)                           93.7 (*p* \< 0.0001)             44.1% (11.5--100)
  Anti-CD19 + anti-CD22      2                  42                         8               19.0%                        17.8% (2.7--42.2)                           69.6% (*p* = 0.0699)             17.0% (5.9--28.0)
  Anti-CD25                  3                  60                         22              36.7%                        42.2% (0.02--98.0)                          97.0% (*p* \< 0.0001)            11.1% (6.7--100)
  BMT                        7                  417                        88              21.1%                        21.7% (12.2--33.1)                          83.9% (*p* \< 0.0001)            15.5% (6.8--52.7)
  Only BMT-related           3                  163                        53              32.5%                        35.5% (14.7--59.6)                          87.5% (*p* = 0.0003)             33.3% (20.8--52.7)
  BMT with other agents      4                  254                        35              13.8%                        14.2% (10.2--18.7)                          0% (*p* = 0.5001)                14.8% (6.8--15.5)

CLS: capillary leak syndome, IL: interleukin, GM-CSF: granulocyte-macrophage colony-stimulating factor, 5-FU: 5-fluorouracil, SS1P: recombinant anti-mesothelin immunotoxin, CD: cluster of differentiation, BMT: bone marrow transplant.
